PriceTargets.com logo

VYNE Therapeutics - VYNE Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.88
  • Forecasted Upside: 175.00%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.50 As of 12/20/2024 06:40 PM ET
▲ +0.11 (4.60%)

This chart shows the closing price for VYNE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New VYNE Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VYNE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VYNE

Analyst Price Target is $6.88
▲ +175.00% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for VYNE Therapeutics in the last 3 months. The average price target is $6.88, with a high forecast of $8.00 and a low forecast of $5.75. The average price target represents a 175.00% upside from the last price of $2.50.

This chart shows the closing price for VYNE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in VYNE Therapeutics. This rating has held steady since July 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/18/2024BTIG ResearchInitiated CoverageBuy$8.00
11/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.75 ➝ $5.75
9/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.75 ➝ $5.75
8/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.75 ➝ $5.75
6/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.75 ➝ $5.75
6/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.75 ➝ $5.75
5/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.75
2/29/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.75
10/30/2023HC WainwrightLower TargetBuy ➝ Buy$28.00 ➝ $5.75
8/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$28.00
5/12/2023Cantor FitzgeraldBoost Target$5.00 ➝ $9.00
4/19/2023HC WainwrightReiterated RatingBuy$28.00
3/30/2023HC WainwrightReiterated RatingBuy$28.00
3/14/2023HC WainwrightReiterated RatingBuy$28.00
8/12/2022Lifesci CapitalDowngradeOutperform ➝ Market Perform
8/10/2022HC WainwrightLower TargetBuy$126.00 ➝ $27.00
6/17/2022HC WainwrightReiterated RatingBuy$126.00
3/18/2022Cantor FitzgeraldReiterated RatingOverweight
12/6/2021HC WainwrightReiterated RatingBuy$126.00
8/16/2021HC WainwrightDowngradeBuy ➝ Neutral
8/13/2021Northland SecuritiesLower TargetSell ➝ Outperform$216.00 ➝ $108.00
5/7/2021HC WainwrightLower TargetBuy$252.00 ➝ $198.00
12/17/2020Maxim GroupReiterated RatingPositive
10/5/2020HC WainwrightBoost TargetBuy$216.00 ➝ $252.00
10/2/2020Lifesci CapitalReiterated RatingOutperform
10/2/2020Northland SecuritiesReiterated RatingBuy$432.00
8/7/2020HC WainwrightLower TargetBuy$252.00 ➝ $216.00
8/6/2020Ci CapitalReiterated RatingBuy$504.00
8/4/2020Northland SecuritiesReiterated RatingBuy
6/1/2020Northland SecuritiesBoost TargetOutperform$252.00 ➝ $432.00
6/1/2020HC WainwrightBoost TargetBuy$180.00 ➝ $252.00
5/21/2020Northland SecuritiesInitiated CoverageOutperform$252.00
5/13/2020BarclaysBoost TargetOverweight$144.00 ➝ $216.00
5/12/2020HC WainwrightBoost TargetBuy$144.00 ➝ $180.00
4/7/2020BarclaysLower TargetOverweight$576.00 ➝ $144.00
4/7/2020HC WainwrightLower TargetBuy$576.00 ➝ $144.00
3/25/2020BarclaysInitiated CoverageOverweight$576.00
3/11/2020Bank of AmericaInitiated CoverageBuy$576.00
2/27/2020HC WainwrightLower TargetBuy$720.00 ➝ $648.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
VYNE Therapeutics logo
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Read More

Today's Range

Now: $2.50
Low: $2.36
High: $2.55

50 Day Range

MA: $2.70
Low: $2.00
High: $3.28

52 Week Range

Now: $2.50
Low: $1.57
High: $3.43

Volume

34,720 shs

Average Volume

70,742 shs

Market Capitalization

$36.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.37

Frequently Asked Questions

What sell-side analysts currently cover shares of VYNE Therapeutics?

The following Wall Street analysts have issued reports on VYNE Therapeutics in the last year: BTIG Research, and HC Wainwright.
View the latest analyst ratings for VYNE.

What is the current price target for VYNE Therapeutics?

0 Wall Street analysts have set twelve-month price targets for VYNE Therapeutics in the last year. Their average twelve-month price target is $6.88, suggesting a possible upside of 175.0%. BTIG Research has the highest price target set, predicting VYNE will reach $8.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $5.75 for VYNE Therapeutics in the next year.
View the latest price targets for VYNE.

What is the current consensus analyst rating for VYNE Therapeutics?

VYNE Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VYNE will outperform the market and that investors should add to their positions of VYNE Therapeutics.
View the latest ratings for VYNE.

What other companies compete with VYNE Therapeutics?

Other companies that are similar to VYNE Therapeutics include Adaptimmune Therapeutics, Black Diamond Therapeutics, Puma Biotechnology, Telomir Pharmaceuticals and Instil Bio. Learn More about companies similar to VYNE Therapeutics.

How do I contact VYNE Therapeutics' investor relations team?

VYNE Therapeutics' physical mailing address is 520 U.S. HIGHWAY 22 SUITE 204, BRIDGEWATER NJ, 08807. The company's listed phone number is (800) 755-7936 and its investor relations email address is [email protected]. The official website for VYNE Therapeutics is vynetherapeutics.com. Learn More about contacing VYNE Therapeutics investor relations.